Format

Send to

Choose Destination
Front Oncol. 2018 Sep 21;8:391. doi: 10.3389/fonc.2018.00391. eCollection 2018.

New Frontiers for the Cytoskeletal Protein LASP1.

Author information

1
Institute for Experimental Biomedicine II, University Clinic, Wuerzburg, Germany.
2
Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, OH, United States.

Abstract

In the recent two decades, LIM and SH3 protein 1 (LASP1) has been developed from a simple actin-binding structural protein to a tumor biomarker and subsequently to a complex, nuclear transcriptional regulator. Starting with a brief historical perspective, this review will mainly compare and contrast LASP1 and LASP2 from the angle of the newest data and importantly, examine their role in transcriptional regulation. We will summarize the current knowledge through pictorial models and tables including the roles of different microRNAs in the differential regulation of LASP1 levels and patient outcome rather than specify in detail all tumor entities. Finally, the novel functional roles of LASP1 in secretion of vesicles, expression of matrix metalloproteinases and transcriptional regulation as well as the activation of survival and proliferation pathways in different cancer types are described.

KEYWORDS:

AP1; LASP1; LASP2; matrix metalloproteinases; nuclear role; transcriptional regulation

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center